CN1054741C - Medicinal composite for eyes - Google Patents
Medicinal composite for eyes Download PDFInfo
- Publication number
- CN1054741C CN1054741C CN95117720A CN95117720A CN1054741C CN 1054741 C CN1054741 C CN 1054741C CN 95117720 A CN95117720 A CN 95117720A CN 95117720 A CN95117720 A CN 95117720A CN 1054741 C CN1054741 C CN 1054741C
- Authority
- CN
- China
- Prior art keywords
- vitamin
- medicine
- mucomembranous surface
- eyes
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a medicinal composite for the eye, which is mainly composed of active substances and oleaginous carriers. The composite forms a solid ointment shape at room temperature, forms a liquid oil shape in hot water and is capable of being atomized into fine particles with water by nebulizers. The medicinal composite for eyes is matched with the nebulizers for use, thereby providing a novel administration system for treating eye disease. The medicinal composite can continuously blow atomized medicine to the eye in order to reach the purpose of treatment.
Description
The present invention relates to a kind of medicinal composite for eyes, particularly about a kind of medicinal composite for eyes for the nebulizer use.
About the atomization medicine of eye usefulness seldom, this is because eyes are comparatively fragile, if used the strong jet eyes that make easily on the contrary to be hurt.For example: Tom. Ji Momen (Thomas J.Zimmerman) of the U.S. was published in last 627 pages to the 628 pages article of ophthalmology's annual report (ANNALS OFOPHTHALMOLGY) in May, 1978, once mention the spraying medicine-releasing system (spray delivery system) of a kind of MISTURA (brand name), but do not disclose any technology contents.Known atomization medicine is to cooperate aerosol can (sprayer) to use, aerosol can is the push agent of drug spray with CFC (chlorofluorocarbon), its atomizing effect is very poor, jet very strong, cause by the therapist eyes uncomfortablely, and CFC will completely forbid use 2000 Christian eras, therefore, no matter pass by or the end, for the therapeutic use of eyes, its research and development are worth all very low.Moreover the medicine that is used in eyes must sterilize, if with aerosol can filling ophthalmic solution, the pot-life is impermanent, and this also is one of known atomization medicine reason that can't be widely used in the treatment eyes.
Main purpose of the present invention is to provide a kind of medicinal composite for eyes for the use of nebulizer system.
Another object of the present invention is to provide a kind of medicinal composite for eyes for nebulizer (nebulizers) use, said composition is the solid grease paste under room temperature, be not easy the antibacterial that grows, and the holding time can be comparatively permanent.
What a further object of the present invention was to provide a kind of sustainability is blown into atomization medicine eyeball surface to reach the new administration system of therapeutic purposes, it need not use CFC as the drug spray propellant, the pollution problem that does not use CFC and caused.
Medical composition of the present invention mainly is made of active substance and oil carrier; Wherein active substance is meant the medicine to eyes tool therapeutic effect, and oil carrier is meant the oil carrier of pharmaceutical grade.
Wherein active substance be the tax of the abirritant that is selected from dry mucous membranes, mucomembranous surface nerve live medicine, mucomembranous surface astringency, mucomembranous surface antibiotic medicine, mucomembranous surface antimicrobial drug, mucomembranous surface antiviral agents, antiallergic agent, ocular hypotensive agents, blood vessel and neurally compose the medicine of living, anti-ly repel at least a in medicine or the ciliary muscle relaxation medicine.
The abirritant of dry mucous membranes, for example: hydroxy ethyl cellulose (hydroxy ethylcellulose), HYDROXY PROPYL METHYLCELLULOSE (hydroxy propyl methyl cell-ulose), gelatin (gelatin), polyvinyl alcohol (polyvinyl alcohol), vitamin A or the like.
The tax of mucomembranous surface nerve medicine alive, for example: vitamin B
1, vitamin B
2, vitamin B
6, vitamin B
12, vitamin C, vitamin E, vitamin K or the like.
The astringency of mucomembranous surface, for example: Camphora (camphor), menthol (menthol), zinc sulfate (zinc sulfate), naphazoline hydrochloride (naphazoline HCl), tetrahydrozoline (tetrahydrozoline), phenylephrine (phenylephrine) or the like.
The antibiotic medicine of mucomembranous surface, for example: fluorine first deoxidation prednisolone (fluoromethol-one), prednisolone acetate (prednisolone acetate), dexamethasone (dexa-methasone) or the like.
The antimicrobial drug of mucomembranous surface and antifungal, for example; Sulfanilamide (sulfanilamide), neomycin (neomycin), oxytetracycline (terramycin), erythromycin (erythromycin), gentamycin (gentamycin) or amphotericin B (amphotericin B) or the like.
The antiviral agents of mucomembranous surface, for example: idoxuridine (idoxuridine) or the like.
Antiallergic agent, for example: antazoline (antazoline), naphazoline (naphazol-ine) or the like.
Ocular hypotensive agents, for example: pilocarpine (pilocarpine), epinephrine (epinephrine) or timolol (timolol) or the like.
Resist and for example repel medicine: cyclosporin A (cyclosporine A) or the like.
Level and smooth muscle relaxant drug, for example: tropicamide (tropicamide), Ah taking off's product (atropine) or the like.
Wherein oil carrier is to be selected from least a in mineral jelly (petrolatum) or the lanoline (lanolin).
Medicinal composite for eyes of the present invention also can add proper additive, for example lecithin or tranquilizer (for example vitamin E) or the like.
The weight of active substance accounts for 0.01 to 20% in the medicinal composite for eyes of the present invention, is preferably 0.1 to 10%, is more preferred from 1 to 15%, and the weight of oils and fats carrier accounts for 80 to 99.99%, is preferably 90 to 99.9%, is more preferred from 95 to 99%.
Compositions of the present invention is the solid grease paste under the greenhouse, then be to be melted into oily in 30 ℃ to 100 ℃ hot water.Therefore, in the time compositions of the present invention will being atomized, be that said composition is placed hot water, be preferably in 60 ℃～80 ℃ the hot water, ultrasound wave by nebulizer is atomized into minuteness particle with it then, these minuteness particles are the formed liquid particles of the present composition and water, these minuteness particles can be blowed lightly to the sufferer eyeball surface to reach the purpose of treatment.
The present invention can obtain better understanding by following embodiment, but invention which is intended to be protected is not limited to these embodiment: embodiment 1 (compositions of treatment xerophthalmia)
1, Formulation Example 1
Mineral jelly 94 grams
Camphora 5 grams
Menthol 1 gram
Vitamin A 500000 (IU represents iu).
2, spray test:
The compositions of getting above-mentioned Formulation Example 1 places medicine glass to add 60 ℃ hot water 5g for about 1 g, said composition is oily and is suspended on the water layer at this moment, it is placed nebulizer, carry out ultrasound vibration atomizing, its skin of the minuteness particle that atomizes out is a lipotropy, internal layer is a hydrophilic, and temperature is about 25 ℃.Embodiment 2 (compositions of treatment chronic conjunctivitis)
1, Formulation Example 2
Mineral jelly 88 grams
Camphora 9 grams
Menthol 2 grams
Vitamin B
1220 milligrams
2, spray test:
Repeat the spray test of embodiment 1 but replace the compositions of Formulation Example 1 with above-mentioned Formulation Example 2 compositionss.Its skin of the minuteness particle that atomizes out is a hydrophilic for the lipotropy internal layer, and temperature is about 25 ℃.
By above embodiment and explanation, can understand compositions of the present invention and can be atomized into molecule with water via the supersonic oscillations of nebulizer really, the present invention successfully provides the treatment eyes more lasting safer more effective new administration system.
Claims (5)
1, a kind of pharmaceutical composition that is used for the treatment of eyes, it comprises the mixture of following atomizing
(1) a kind of eye medicine combination comprises:
(a) part by weight is at 0.01 to 20% active substance, and this active substance is live antimicrobial drug, and the antiviral agents of antifungal, mucomembranous surface, antiallergic agent, ocular hypotensive agents, blood vessel and neurally compose the medicine of living, anti-ly repel a kind of in medicine or the smooth muscle relaxant of antibiotic medicine, mucomembranous surface of astringency, mucomembranous surface of medicine, mucomembranous surface of the tax of the abirritant that is selected from dry mucous membranes, mucomembranous surface nerve; And
(b) part by weight is at 80 to 99.99% oil carrier, and it is to be selected from least a in pharmaceutical grade vaseline or the lanoline; And
(2) temperature is higher than the water of this carrier fusing point.
2, compositions as claimed in claim 1, wherein the part by weight of this active substance is 0.1 to 10%, and the part by weight of this oil carrier is 90 to 99.9%
3, as the compositions of claim 1 or 2, wherein this active matter is a hydroxy ethyl cellulose, hydroxy propyl cellulose, gelatin, polyvinyl alcohol, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin E, vitamin K, Camphora, menthol, zinc sulfate, naphazoline hydrochloride, tetrahydrozoline, phenylephrine, fluorine first deoxidation prednisolone, the prednisolone acetate, De Saimisong, sulfanilamide, neomycin, oxytetracycline, erythromycin, gentamycin, amphotericin B, idoxuridine, antazoline, naphazoline, pilocarpine, epinephrine, timolol, cyclosporin A, tropicamide, atropine.
4, as the eye medicine combination of claim 1 or 2, wherein this active substance is selected from Camphora or menthol.
5, as the eye medicine combination of claim 1 or 2, wherein said composition further includes emulsifying agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95117720A CN1054741C (en) | 1995-10-09 | 1995-10-09 | Medicinal composite for eyes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95117720A CN1054741C (en) | 1995-10-09 | 1995-10-09 | Medicinal composite for eyes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1147376A CN1147376A (en) | 1997-04-16 |
| CN1054741C true CN1054741C (en) | 2000-07-26 |
Family
ID=5081340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95117720A Expired - Fee Related CN1054741C (en) | 1995-10-09 | 1995-10-09 | Medicinal composite for eyes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1054741C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3514724A1 (en) * | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Ointment for the prevention and treatment of disorders of the eyes and skin |
| CN1033936A (en) * | 1987-12-26 | 1989-07-19 | 沈阳市红旗制药厂 | The preparation method of rifampicin eye ointment |
-
1995
- 1995-10-09 CN CN95117720A patent/CN1054741C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3514724A1 (en) * | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Ointment for the prevention and treatment of disorders of the eyes and skin |
| CN1033936A (en) * | 1987-12-26 | 1989-07-19 | 沈阳市红旗制药厂 | The preparation method of rifampicin eye ointment |
Non-Patent Citations (1)
| Title |
|---|
| 《药剂学》第二版 1987.5.1 溪念朱，顾学球，人民卫生出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1147376A (en) | 1997-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2960867B2 (en) | Oil-in-water nanoemulsions useful as ophthalmic vehicles and their preparation | |
| US6656460B2 (en) | Method and composition for dry eye treatment | |
| EP1441696B1 (en) | Method and composition for dry eye treatment | |
| Veloso et al. | Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. | |
| DE1492015A1 (en) | Improved form of administration of pharmaceutical preparations | |
| JP2797069B2 (en) | Ophthalmic pharmaceutical composition and method of administration thereof | |
| WO1992005770A1 (en) | Drug delivery vehicles suspended in nonaqueous perfluorinated carrier | |
| US9801899B2 (en) | Artificial tear emulsion | |
| JP5604395B2 (en) | Microemulsion and its use to prevent airway disease | |
| US20020064503A1 (en) | Composition and method for treatment of otitis media | |
| JPH05500062A (en) | useful compositions | |
| AU2003247976A1 (en) | Ophthalmic compositions containing loratadine | |
| CN1352551A (en) | Preparations for the application of anti-inflammatory agents | |
| WO2005037256A2 (en) | Liquid preparation containing tobramycin | |
| US8940339B2 (en) | Microemulsions and its use for preventing airway diseases | |
| CN1054741C (en) | Medicinal composite for eyes | |
| US7064132B2 (en) | Composition and method for treatment of otitis external | |
| EP1461091A2 (en) | Composition and method for decreasing upper respiratory airway resistance | |
| AU2004246961B2 (en) | Transnasal microemulsions containing diazepam | |
| WO2017066429A1 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| US20090270335A1 (en) | Collyrium for dry eye | |
| JPH04300833A (en) | Prostaglandin e1-containing fat emulsion-loaded aerosol | |
| Patel et al. | Lipid prodrug approach for retina and posterior segment disease | |
| US20220175878A1 (en) | Method for preparing eye drops of cyclosporin a | |
| DE112019000683T5 (en) | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS OF TREATMENT OF DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20000726 Termination date: 20111009 |